Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digital Cognitive Training and PCSK9 Inhibitor in Intracranial Atherosclerotic Stenosis
NCT07605130Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of recaticimab in intracranial atherosclerosis (ICAD) and cognitive impairment (4 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Change from baseline in composite cognitive Z-score at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
recaticimab
03
Conditions
intracranial atherosclerosis (ICAD)cognitive impairment
Beyond the preview
Go deeper on NCT07605130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605130.